Novartis AG (NVS) annual results, year to 31 December 2016: revenue USD 48,518 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2016 it reported revenue from the sale of goods of USD 48,518 million. Its profit attributable to shareholders was USD 6,712 million, and diluted earnings per share USD 2.80.
The year to 31 December 2016
| Year to | Dec 2016 |
|---|---|
| Revenue from the sale of goods | 48,518 |
| Cost of sales | 17,520 |
| Gross profit | 31,916 |
| Research and development | 9,039 |
| Selling, general and administrative | 14,192 |
| Operating profit | 8,268 |
| Profit before tax | 7,817 |
| Income tax | 1,119 |
| Profit for the year | 6,698 |
| Profit attributable to shareholders | 6,712 |
| Filing | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
| Year to | Dec 2016 |
|---|---|
| Diluted EPS | 2.80 |
| Basic EPS | 2.82 |
| Filing | 20-F |
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2016 |
|---|---|
| Cash from operations | 11,475 |
| Purchase of property, plant and equipment | 1,862 |
| Free cash flow | 9,613 |
| Dividends paid | 6,475 |
| Filing | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2016 |
|---|---|
| Equity attributable to shareholders | 74,891 |
| Cash and cash equivalents | 7,007 |
| Filing | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2016 |
|---|---|
| Return on year-end equity | 9.0% |
| Effective tax rate | 14.3% |
| Filing | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016, this page
Source
20-F for the year to 31 December 2016, filed 30 January 2019, accession 0001370368-19-000002: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.